Japan’s new policy mix

Japan revised its Q3 GDP growth up from 0.2% to 1.8% qoq ann. Accordingly, we lifted our 2019 GDP forecast slightly up to 1.1%. After the October sales tax hike from 8% to 10%, indicators have come in mixed. The BoJ’s Tankan survey showed business confidence at large manufacturers dropping. We continue to expect a negative GDP growth rate in Q4.

Highlights:

  • Japan revised its Q3 GDP growth up from 0.2% to 1.8% qoq ann. Accordingly, we lifted our 2019 GDP forecast slightly up to 1.1%.
  • After the October sales tax hike from 8% to 10%, indicators have come in mixed. The BoJ’s Tankan survey showed business confidence at large manufacturers dropping. We continue to expect a negative GDP growth rate in Q4.
  • In order to minimize the risks after the tax hike but also to avoid a cliff edge after the Tokyo Olympics next summer, PM Abe announced a stimulus package with a headline figure of JPY 26tr (4.7% of GDP). Actual fiscal measures will be much lower with JPY 13.2 tr and the impact on the economy even smaller. We revised our growth outlook upwards to 0.6% next year.
  • With the new policy package, Japan shifted to a new policy mix. We expect the BoJ to hold its monetary policy constant on its next meeting (December 18/19) and at least during the next year.

Download the full publication below

JAPAN’S NEW POLICY
MIX

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.